CClinicalTrials.gg
CompletedNCT03411889Updated Mar 25, 2022

A Feasibility Study to Develop a Protocol for Functional Lacrimal Magnetic Resonance Imaging

An interventional study of MRI scanning in Lacrimal Duct Obstruction and Lacrimal Stenosis, sponsored by Brighton and Sussex University Hospitals NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Brighton and Sussex University Hospitals NHS Trust · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Watering eyes (epiphora) is a very common ophthalmic condition. It is frequently caused by dysfunction of the lacrimal (tear) drainage system which is the 'pipework' that takes tears from the eye to the nasal cavity. If the system is completely blocked then the patient is offered surgery to unblock or bypass the obstruction. However, the system is often either partially obstructed, or there is tear drainage delay despite there being no apparent obstruction (functional obstruction). Currently this is investigated with two separate scans, conducted at different times in different departments (CT and nuclear medicine). These are dacryocystography (DCG) and dacryoscintigraphy (DSG) and both are required as they have different limitations and benefits. Moreover DCG is a CT scan that uses radiation.

Functional magnetic resonance dacryocystography (MR DCG) is increasingly widely used in other fields of medicine (e.g. cardiology) because of the increasing acquisition speed and resolution of MRI scanners in recent years. The investigators anticipate functional MRI of the lacrimal drainage system (i.e. scanning as eye drops are instilled and pass down the system) will overcome the shortcomings of DCG and DSG, by simultaneously providing both good anatomical detail and physiological images. Various methods of MR DCG have been described in the literature and there is no standard protocol for this procedure as of current. In this study, the investigators aim to develop a protocol for MR DCG that can be used in routine radiological practice in place of DCG and DSG and get pilot data on tear drainage in participants with known delayed tear drainage and controls with normal tear drainage systems.

Read the detailed description

Tear drainage delay is a common problem that causes a watery eye. This can impair activities of daily living such as reading and driving, can be a huge nuisance requiring continual dabbing with a tissue and can cause infections and abscesses of the tear drainage system. The current, standard investigations for tear drainage delay have significant limitations with two separate scans in separate departments being required. A functional MRI scan would be able to combine these two scans and provide both better anatomical and functional detail than each one respectively. This would have several major benefits:

  1. Improved diagnostic information to guide the treatment choice
  2. Reduced scan resource usage as one scan would provide all the required functional anatomical and functional information.
  3. Improved patient convenience
  4. Improved safety as radiation is used for CT DCG, where MRI The study involves investigation of both controls with normal tear drainage and individuals with known tear drainage delay. Both groups are required for the development of the protocol as the speed of tear transit will differ greatly which will facilitate optimisation of the MRI scan protocol. This will also provide preliminary data on the speed of tear passage in a normal lacrimal drainage system and in an impaired system.

Several other functional lacrimal drainage MRI studies have been done. However, a clear protocol has not been developed and there is no data on normal and abnormal MRI appearances and tear transit times.

The normal standard of care will not be delayed by this investigation as it will be conducted while patients are awaiting other lacrimal investigations (DCG and DSG) or lacrimal surgery, none of which would be affected by this study.

02

Conditions studied

  • Lacrimal Duct Obstruction
  • Lacrimal Stenosis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Lacrimal drainage disease participants (n=5)

    1. Symptomatic epiphora (tearing)
    2. Nasolacrimal drainage dysfunction confirmed by the following characteristics:

      1. An abnormal delay of tear transit on DSG
      2. A normal DCG and lacrimal syringing investigation
      3. Normal eyelid and punctal anatomy

Controls

  1. No epiphora
  2. Normal lacrimal syringing in clinic.

Exclusion criteria

  1. Age under 18
  2. Renal function \<30mL/min/1.73m2
  3. Contra-indications to MRI e.g. electronic or metal implants, severe claustrophobia
  4. Known adverse reactions to contrast agents
  5. Pregnancy

Exclusion Criteria:

-

04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    functional lacrimal delay

    Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage

    Diagnostic Test: MRI scanning

Interventions

  • Diagnostic testMRI scanning

    MRI scanning during tear drainage

    Also known as: functional MRI

05

What researchers measure

Primary outcomes

  1. A protocol for functional MRI scanning

    This is a feasibility study for functional MRI scanning. The primary outcome is a MRI scanning protocol that can be routinely used to assess the 'real-time' drainage of lacrimal flow

    Time frame: 60 minutes. This is a feasibility study in which participants are seen on one occasion and have one MRI scan which is expected to take around 60 minutes

06

Study locations

1 site
  • Brighton & Sussex University Hospitals
    Brighton, East Sussex BN" 5BE, United Kingdom
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03411889
Lead sponsor
Brighton and Sussex University Hospitals NHS Trust
Responsible party
Sponsor
First posted
Jan 26, 2018
Start date
Jun 13, 2018
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019
Last update
Mar 25, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion